treatment with secukinumab or ixekizumab over treatment with tofacitinib (new, PICO 61). The use of secukinumab and ixekizumab in patients with active AS is supported by data from large placebo-controlled trials (see Supplementary Appendix 6, on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41042/ abstract In adults with active AS despite treatment with NSAIDs and who have contraindications to TNFi, we conditionally recommend treatment with